Home Healthcare IT Radiodermatitis Market Size, Share & Growth Analysis Report 2031

Radiodermatitis Market

Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Oral Drugs, Dressings), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI54200DR
Study Period 2019-2031 CAGR 4.52%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 492 Million
Forecast Year 2031 Forecast Year Market Size USD 732 Million
Largest Market Asia Pacific Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global radiodermatitis market size was valued at USD 492 million in 2022. It is projected to reach USD 732 million by 2031, growing at a CAGR of 4.52% during the forecast period (2023–2031). Factors such as rise in the adoption of radiotherapy and higher radiodermatitis cost, significantly drives the radiodermatitis market demand by 2031.

Radiodermatitis, commonly known as radiation dermatitis, is an uncommon illness produced by cancer and non-cancer radiation therapy that significantly impacts a patient's physical health and quality of life. In addition, over half of individuals undergoing cancer treatment have undergone radiation therapy during the disease, and almost all have experienced some cutaneous sensitivity. Numerous benefits are associated with topical products, including low cost, simple application, accessibility, and minimized adverse effects. Dressings are enough to treat different levels of radiation burns, which will likely increase their use in the future. Radiodermatitis can cause a variety of skin symptoms, including Redness, Dryness, Itching, Pain, Blistering, Peeling, Ulceration, etc

Market Dynamics

What are the Primary Factors driving the Radiodermatitis Market?

Rise in the Adoption of Radiotherapy

Radiotherapy treats cancer by exposing the patient to varying radiation levels to destroy cancer cells and reduce the size of malignant tumors. One typical side effect of radiotherapy is radiation dermatitis. On the other hand, radiation therapy takes time to eliminate cancer cells. DNA damage causes growth retardation. Furthermore, treatment can take several days to many weeks before causing enough damage to DNA for cancer cells to die. The degree of skin damage caused by radiation varies from person to person. The symptoms range from modest redness and itching to painful, damaged skin prone to infection in certain people.

What are the Main Factors that will slow down the Radiodermatitis Market?

Higher Radiodermatitis Cost

There is a considerable investment being made by the pharmaceutical industry in the search for cancer therapies that are both effective and safe. Despite the lack of a cure for cancer, advances in technology and the development of new therapeutic agents have shown encouraging results in managing the disease's symptoms. Variations in radiation costs are very sensitive to patient and illness characteristics and geographic and practitioner-specific factors. When radiodermatitis products are deemed medically necessary, they are covered by the NHS in the UK. Patients with radiation dermatitis can seek compensation from a variety of insurance providers. In addition, developing countries often face financial difficulties while trying to treat cancer due to the high cost of care. The expansion of the market is hindered by the high price of products, particularly dressings like honey-impregnated and silicone dressings.

What are the Future Opportunities for Radiodermatitis Market?

Increased Demand for Radiation Therapy Side Effect Reduction

Aging populations and higher cancer survival rates are expected to cause sustained growth in the need for oncology services in the coming years. For instance, people aged 85 and over are expanding faster than any other age group worldwide. The risk of developing cancer rises with age, reaching its highest point in men and women in their 80s. Further, radiodermatitis affects more than half of all cancer patients undergoing radiotherapy. Around 95% of all cancer patients undergoing radiation therapy develop radiodermatitis, a significant side effect directly resulting from radiation exposure. There are two distinct times when radiodermatitis manifests itself after treatment: right away, within the first week, or months or even years later. Acute radiodermatitis is a form of burn injury that can range in severity depending on the individual's response to therapy and other circumstances.

Regional Analysis

The global radiodermatitis market share is segmented by product and distribution channel.

Based on product, the global market for radiodermatitis is bifurcated into topical, oral drugs, and dressings.

The topical segment is the highest contributor to the market. Gels, creams, lotions, and ointments are all examples of topical products used on the skin, nails, vagina, or mucous membranes for localized treatment. For instance, radiodermatitis can be treated with topical corticosteroids for 2–4 weeks. They are crucial in the treatment of a wide range of skin disorders. Several benefits are associated with topical treatment, including low cost, convenience, wide availability, and few or no adverse side effects. The expansion of the market is anticipated to be fueled by these aspects throughout the predicted time frame.

Based on the distribution channel, the global radiodermatitis market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.

The retail pharmacysegment is the highest contributor to the market.Brand name and generic medications are available on prescription from a retail pharmacy. Due to the widespread distribution of retail pharmacies, a sizable clientele has come to rely on them. If the prescription treatment for radiodermatitis is not accessible, these pharmacies offer alternatives. Customers are more likely to shop at retail pharmacies because of their services, such as stock monitoring, urging customers to buy pharmaceuticals and recommend prescriptions, and better financial and debt management for patients. As a result, the future year should see increased market activity due to the abovementioned variables. In addition, people favor retail pharmacies since they are the most established and widespread channel for delivering radiation dermatitis medications to end users.

Report Scope

Report Metric Details
Segmentations
By Product
  1. Topical
  2. Oral Drugs
  3. Dressings
By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
Company Profiles Bausch Health Companies INC. BMG Pharma S.P.A. Convatec Group PLC. GlaxoSmithKline PLC Helsinn Healthcare SA Molnlycke Health Care AB Stratpharma AG.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global radiodermatitis market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

Asia-Pacific Dominates the Global Market

Asia-Pacificis the most significant shareholder in the global radiodermatitis market. China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific are all part of Asia-Pacific. High incidences of cancer and other chronic diseases and the constant rise in healthcare costs are the primary forces pushing the market forward. The region's market expansion is fueled in part by the intensification of research and development and the proliferation of new products. Radiation dermatitis is a growing problem as the number of people receiving radiation therapy rises. Since radiodermatitis can progress to a life-threatening condition, and a patient may even perish from radiation exposure increases the demand for goods designed to treat this condition.

Europe is expected to grow during the forecast period.The most important sources of this region's revenue come from Germany, the United Kingdom, France, Italy, Spain, and the rest of Europe. An aging population and a growing cancer patient population point to significant future expansion for the market. For instance, although Europe only accounts for one-eighth of the world's population, it accounts for around one-quarter of all cancer diagnoses, with about 3.7 million new patients each year and 50% of cancer patients having radiation therapy. The European projection period for cancer biomarkers is anticipated to be bolstered further by these variables.

Due to rising cancer rates in the country, substantial R&D spending, and an uptick in new product releases, the United States is projected to hold a disproportionately significant share of North America's radiodermatitis market throughout the forecast period. In addition, breast cancer has the highest incidence rate of any female tumor in the area. The rising popularity of radiation therapy is also projected to be a key factor propelling the regional market. Market expansion is also aided by the major firms' massive R&D expenditures. There has been a significant uptick in business alliances and mergers, another factor propelling this industry.

Brazil, Saudi Arabia, South Africa, and the Rest of LAMEA are all part of the LAMEA region. Due to the rising geriatric population and the frequency of various cancers, this region is attracting investment from new companies in the radiation dermatitis market. High-quality services are in high demand because of rising incomes in some population clusters. The government has expanded its spending on the industry to entice established pharmaceutical companies to set up shops in the region.

Market Size By Product

Recent Developments

  • September 2022- Bayer and Perdue AgriBusiness have announced an innovative partnership to lower greenhouse gas emissions and increase sustainability throughout the food value chain.
  • October 2022- GSK updates ContRAst phase III program for otilimab in the treatment of mild and moderate rheumatoid arthritis.

Top Key Players

Bausch Health Companies INC. BMG Pharma S.P.A. Convatec Group PLC. GlaxoSmithKline PLC Helsinn Healthcare SA Molnlycke Health Care AB Stratpharma AG. Others

Frequently Asked Questions (FAQs)

How big is the radiodermatitis market?
The global radiodermatitis market size was valued at USD 492 million in 2022. It is projected to reach USD 732 million by 2031, growing at a CAGR of 4.52% during the forecast period (2023–2031).
Europe has the highest growth rate in the radiodermatitis market.
Key verticals adopting the global market include: Bayer AG., Bausch Health Companies INC., BMG Pharma S.P.A., Convatec Group PLC., GlaxoSmithKline PLC, Helsinn Healthcare SA, Molnlycke Health Care AB, and Stratpharma AG.
The rise in the adoption of radiotherapy is the key driver for the growth of the global market.
Increased demand for radiation therapy side effect reduction is one of the upcoming key trends in the global market.


We are featured on :

This website uses cookies to ensure you get the best experience on our website. Privacy Policy